Tirzepatide therapy increased both IGFBP-1 and IGFBP-2 levels in patients with T2DM, while the comparator drug, the GLP-1 RA dulaglutide, did not influence the levels of the studied IGFBPs [23]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.